ACAN and osteoarthritis: Aggrecan serves as a validated biomarker of cartilage anabolic activity in clinical PTOA assessment, while CTX-II represents an established serum and synovial fluid biomarker for monitoring type II collagen degradation in osteoarthritis patients.